Last Updated:
It is very rare for FIIs and DIIs to agree in the stock market, but when it happens, investors become alert. In the July-September quarter, there are two stocks on which both foreign and domestic investors have placed strong bets. This indicates that these companies are seeing strong long-term growth prospects.
New Delhi. Large institutional investors in the Indian stock market generally do not adopt the same strategy. But this time Utkarsh Small Finance Bank and Sai Life Sciences were the two stocks in which both the parties increased investment rapidly. DIIs have increased their stake in Utkarsh Bank by 7.92 percent and FIIs by 11.22 percent. Similarly, the share of FIIs in Sai Life Sciences reached 22.5 percent and that of DIIs reached 29.9 percent. This unusual combination of institutional investment shows that both the companies are performing strongly in their respective sectors.
Utkarsh Bank strengthens its hold in the rural market
The biggest strength of Utkarsh Small Finance Bank is its strong network in rural and semi-urban areas. Digital banking has still not reached many places in the country, and this bank is becoming a reliable option for such customers. It has 1,104 banking outlets, 778 micro-ATMs and 296 unbanked rural centres. The bank’s huge network in Bihar and UP has been its main growth driver. Now the bank is also expanding into new geographical areas, due to which the customer base is expected to increase further in the coming time.
Sai Life Science: Big player in global pharma
Hyderabad-based Sai Life Sciences is a global CRDMO company with more than 300 international customers. It has a strong presence in major markets like America, Europe, Japan and UK. The company holds 100% clearance record from major organizations like USFDA and PMDA, which is an indication of its quality and trust. From drug discovery to API manufacturing, the company is known for providing end-to-end solutions in the pharma sector. This is the reason why institutional investors have rapidly increased investment in it.
Business will grow further due to tremendous capex plan
Sai Life Science has prepared a big capex plan of Rs 700 crore for FY26. The company is developing a new manufacturing site in Hyderabad, which will increase the production capacity from 700 KL to 1,150 KL by FY26. Its capacity is expected to double by FY27. This expansion will further strengthen the company’s global supply chain and pharma business. These future growth prospects are attracting FIIs and DIIs towards this stock.
(Disclaimer: The stocks mentioned here are for informational purposes only. If you want to invest money in any of these, then first consult a certified investment advisor. StuffUnknownwill not be responsible for any profit or loss of yours.)
